Discussion
Data demonstrates the widespread use of oral trials across the hospital,
with 19.5% (N=118) of patients on the dysphagia caseload being offered
oral trials. Neurological diagnosis appears to be a defining factor to
whether oral trials are offered. Due to the limited sample size and
interaction between variables, it is not possible to determine the
extent to which other factors contribute independently to treatment
group. However, data begins to reveal clear trends as to when and where
oral trials are offered.